

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Sheet 01 of 12  
RECEIVED  
TECH CENTER 1001/2900  
DEC 26 2001

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1780R1	Serial No. 09/803,341
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Miller et al.	
		Filing Date 20 Mar 2001	Group 16

U.S. PATENT DOCUMENTS


Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
my ↓	1	4,816,567	28.03.89	Cabilly et al.			19.12.90
	2	4,968,603	06.11.90	Slamon et al.			
	3	5,183,884	02.02.93	Kraus et al.			
	4	5,434,340	18.07.95	Krimpenfort et al.			
	5	5,480,968	02.01.96	Kraus et al.			
	6	5,530,101	25.06.96	Queen et al.			
	7	5,545,806	13.08.96	Lonberg et al.			
	8	5,545,807	13.08.96	Surani et al.			
	9	5,569,825	29.10.96	Lonberg et al.			
	10	5,591,699	07.01.97	Hodge, R.			
	11	5,591,828	07.01.97	Bosslet, K. et al.			
	12	5,595,721	21.01.97	Kaminski et al.			
	13	5,641,869	24.06.97	Vandlen et al.			
	14	5,641,870	24.06.97	Rinderknecht et al.			
	15	5,677,171	14.10.97	Hudziak et al.			
	16	5,736,137	07.04.98	Anderson et al.			
	17	5,783,186	21.07.98	Arakawa et al.			
	18	5,821,337	13.10.98	Carter et al.			
	19	5,824,311	20.10.98	Greene et al.			
	20	5,959,083	28.09.99	Bosslet et al.			
	21	5,989,830	23.11.99	Davis et al.			
	22	6,027,725	22.02.00	Whitlow et al.			
	23	6,066,719	23.05.00	Zapata			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
my ↓ ✓	24	307,247 B1	15.03.89	EPO				
	25	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	26	517,024	18.05.92	EPO				
	27	599,274	01.06.94	EPO				
	28	628,078	08.12.99	EPO				
	29	870,827 A2	14.10.98	EPO				
	30	WO 00/06605 ✓	10.02.00	PCT				
	31	WO 90/14357	29.11.90	PCT				
	32	WO 91/05264	18.04.91	PCT				
	33	WO 91/19515	26.12.91	PCT				

Examiner <i>Mark Y</i>	Date Considered 3-10-03
---------------------------	----------------------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




RECEIVED  
DEC 26 2001  
TECH CENTER 1600

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1780R1	Serial No. 09/813,341
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Miller et al.	
		Filing Date 20 Mar 2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
my ↓	34	WO 94/00136	06.01.94	PCT				
	35	WO 94/13804	23.06.94	PCT				
	36	WO 94/15642	21.07.94	PCT				
	37	WO 94/22478	13.10.94	PCT				
	38	WO 95/09917	13.04.95	PCT				
	39	WO 97/01633	16.01.97	PCT				
	40	WO 97/14719	24.04.97	PCT				
	41	WO 97/25428	17.07.97	PCT				
	42	WO 98/17797	30.04.98	PCT				
	43	WO 98/18921	07.05.98	PCT				
	44	WO 98/28426	02.07.98	PCT				
	45	WO 98/32856	30.07.98	PCT				
	46	WO 98/35986	20.08.98	PCT				
	47	WO 98/39361	11.09.98	PCT				
	48	WO 98/41629	24.09.98	PCT				
	49	WO 98/43089	01.10.98	PCT				
	50	WO 98/46643	22.10.98	PCT				
	51	WO 98/46751	22.10.98	PCT				
	52	WO 98/51793	19.11.98	PCT				
	53	WO 98/58965	30.12.98	PCT				
	54	WO 99/02567	21.01.99	PCT				
	55	WO 99/02653	21.01.99	PCT				
	56	WO 99/04001	28.01.99	PCT				
	57	WO 99/07738	18.02.99	PCT				
	58	WO 99/09165	25.02.99	PCT				
	59	WO 99/11791	11.03.99	PCT				
	60	WO 99/23221	14.05.99	PCT				
	61	WO 99/33980	08.07.99	PCT				
	62	WO 99/37684	29.07.99	PCT				
	63	WO 99/37791	29.07.99	PCT				
	64	WO 99/57150	11.11.99	PCT				
	65	WO 99/60846	02.12.99	PCT				
	66	WO 99/64461	16.12.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)		
my	67	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
↓	68	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation" <u>Blood</u> 63(6):1424-1433 (1984)
Examiner <i>[Signature]</i>		Date Considered 3-10-03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

07813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

2644

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	69	Armitage et al., "Molecular and biological characterization of a murine ligand for 40" <u>Nature</u> 357(6373):80-82 (1992)
	70	Arteaga et al., "p185 <sup>c-erbB-2</sup> Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
	71	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5381):1305-1308 (1998)
	72	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
	73	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
	74	Baldwin, A., "The NF- $\kappa$ B and I $\kappa$ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
	75	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	76	Baselga and Mendelsohn, "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
	77	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 <sup>HER2</sup> Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
	78	Bindon et al., "Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q" <u>Journal of Experimental Medicine</u> 168(1):127-142 (July 1988)
	79	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	80	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
	81	Borrebaeck et al., "Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes" <u>Proc. Natl. Acad. Sci. USA</u> 85(11):3995-3999 (Jun 1988)
	82	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)
	83	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	84	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
	85	Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991)
	86	Browning et al., "Lymphotoxin $\beta$ , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
	87	Bruggemann, M. et al., "Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies" <u>Journal of Experimental Medicine</u> 166:1351-1361 (1987)
✓	88	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (1992)

Examiner

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Sheet 04 of 12

Serial No.

09/813 741

Applicant

Miller et al.

Filing Date

20 Mar 2001

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	89	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
	90	Carraway et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <u>Nature</u> 387:512-516 (May 1997)
	91	Chang et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <u>Nature</u> 387:509-512 (May 29, 1997)
	92	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
	93	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
	94	Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" <u>Journal of Molecular Biology</u> 186:651-663 (1985)
	95	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)
	96	Coloma and Morrison, "Design and production of novel tetravalent bispecific antibodies" <u>Nature Biotechnology</u> 15(2):159-163 (Feb 1997)
	97	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)
	98	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991)
	99	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)
	100	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
	101	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- $\kappa$ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)
	102	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs" <u>Cancer Biotherapy &amp; Radiopharmaceuticals</u> 12(3):177-186 (1997)
	103	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)
	104	Drebin et al., "Monoclonal Antibodies Reactive With Distinct Domains of the neu Oncogene-Encoded p185 Molecule Exert Synergistic Anti-Tumor Effects In Vivo" <u>Oncogene</u> 2:273-277 (1988)
	105	Duchosal et al., "Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries" <u>Nature</u> 355(6357):258-262 (Jan 16, 1992)
	106	Earp et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <u>Breast Cancer Res and Treatment</u> 35:115-132 (1995)
	107	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" <u>EMBO Journal</u> 7(3):711-717 (1988)
✓	108	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL" <u>Journal of Biological Chemistry</u> 273(23):14363-14367 (1998)

Examiner

*March 7*

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

89/813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	109	Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
	110	Garrard and Henner, "Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops" <u>Gene</u> 128(1):103-109 (Jun 15, 1993)
	111	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells" <u>Proc. Natl. Acad. Sci. USA</u> 94(14):7509-7514 (Jul 8, 1997)
	112	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol</u> 7:R750-R753 (1997)
	113	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular &amp; Cellular Biology</u> 11:3020-3026 (1991)
	114	Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991)
	115	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)
	116	Gram et al., "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library" <u>Proc. Natl. Acad. Sci. USA</u> 89(8):3576-3580 (Apr 15, 1992)
	117	Gras et al., "BCMAP: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes" <u>Int. Immunology</u> 7:1093-1106 (1995)
	118	Greenwood et al., "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis" <u>Therapeutic Immunology</u> 1(5):247-255 (Oct 1994)
	119	Griffiths et al., "Human Anti-Self Antibodies With High Specificity From Phage Display Libraries" <u>EMBO Journal</u> 12(2):725-734 (1993)
	120	Groenen et al., "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)
	121	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
	122	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth" <u>Journal of Experimental Medicine</u> 188(6):1185-1190 (1998)
	123	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
	124	Hale, G. et al., "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H" <u>Lancet</u> 2(8625):1394-1399 (Dec 17, 1988)
	125	Hanasaki Kohji et al., "Binding of Human Plasma Sialoglycoproteins by the B Cell-Specific Lectin CD22: Selective Recognition of Immunoglobulin M and Haptoglobin" <u>Database Biosis</u> (Accession No. PREV199598267581) (XP002177287)
	126	Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)
	127	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)
✓	128	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF $\alpha$ )" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)

Examiner

Mitsuki

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

69/613,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

164

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	129	Holmes et al., "Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup> " <u>Science</u> 256:1205-1210 (May 22, 1992)
	130	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	131	Hoogenboom, Hennie R., "Mix and Match: Building Manifold Binding Sites" <u>Nature Biotechnology</u> (XP-002084229) 15(2):125-126 (Feb 1997)
	132	Hudziak et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular &amp; Cellular Biology</u> 9(3):1165-1172 (Mar 1989)
	133	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)
	134	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
	135	Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986)
	136	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
	137	Jones, P.T. et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
	138	Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990)
	*139	Kabat <u>Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)
	140	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)
	141	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis" <u>Leukemia Research</u> 11(12):1119-1125 (1987)
	142	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
	143	Klapper et al., "A Subclass of Tumor-Inhibitory Monoclonal Antibodies to ErbB-2/HER2 Blocks Crosstalk With Growth Factor Receptors" <u>Oncogene</u> 14:2099-2109 (1997)
	144	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
	145	Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" <u>Blood</u> 84:1415-1420 (1994)
	146	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)
	147	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
↓	148	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)

Examiner

Mishra

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

Applicant  
Miller et al.

Filing Date

20 Mar 2000

Group

2004

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	149	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 11(2):979-986 (Feb 1991)
	150	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma" <u>EMBO Journal</u> 11:3897-3904 (1992)
	151	Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed" <u>Nucleic Acids Research</u> 22:1147-1154 (1994)
	152	Lee et al., "Transforming Growth Factor $\alpha$ : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)
	153	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)
	154	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)
	155	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
	156	Lewis et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)
	157	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)
	158	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
	159	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family" <u>J. Leukocyte Biol.</u> 60:1-7 (1996)
	160	Love et al., "Recombinant antibodies possessing novel effector functions" <u>Methods in Enzymology</u> 178:515-527 (1989)
	161	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
	162	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations" <u>Journal of Experimental Medicine</u> 190:1697-1710 (1999)
	163	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily" <u>Int. Immunology</u> 10:1693-1702 (1998)
	164	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)
	165	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - A Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9(4):1063-1068 (April 1990)
	166	Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (nhl) cell lines" <u>Blood</u> (Abstract #2535) 88(10):637a (1996)
	167	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling" <u>Bio/Technology</u> 10:779-783 (1992)
	168	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)

Examiner

Mioosh 2

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

my	169	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	170	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	171	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	172	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- $\kappa$ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
	173	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
	174	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)
	175	McKenzie et al., "Generation and Characterization of Monoclonal Antibodies Specific for the Human neu Oncogene Product, p185" <u>Oncogene</u> 4:543-548 (1989)
	176	Miller, R. et al., "Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma" <u>Blood</u> 62:988-995 (1983)
	177	Mongkolkeha et al., "Cutting Edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 160(1):3-6 (1998)
	178	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
	179	Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator" <u>Science</u> 285(5425):260-263 (1999)
	180	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)
	181	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 <sup>erbB2</sup> " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)
	182	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor- $\kappa$ B, and c-Jun NH <sub>2</sub> -Terminal Kinase" <u>Journal of Biological Chemistry</u> 274:15978-15981 (1999)
	183	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185 <sup>neu</sup> " <u>Methods in Enzymology</u> 198:277-290 (1991)
	184	Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes" <u>J. Immunol.</u> 131(1):244-250 (Jul 1983)
	185	Nadler et al., "Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies" <u>Progress in Hematology</u> , Brown, E., Grune & Stratton, Inc. Vol. XII:187-225 (1981)
	186	Nadler, L., "B Cell/Leukemia Panel Workshop: Summary and Comments (Chap. 1)" <u>Lymphocyte Typing II</u> , Renling et al., Springer Verlag Vol. 2:3-37 and Appendix (1986)
	187	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
✓	188	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)

Examiner

Misodk y

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

08/813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1-2001

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

189	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological receptor function" <u>Nature</u> 314:268-270 (March 21, 1985)
190	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(12):6216-6221 (1997)
191	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
192	Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" <u>Proc. Natl. Acad. Sci. USA</u> 82(14):4592-4596 (Jul 1985)
193	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
194	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor" <u>FEBS Letters</u> 431(3):351-356 (1998)
195	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
196	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling" <u>FEBS Letters</u> 424(1-2):41-45 (1998)
197	Pietras et al., "Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" <u>Oncogene</u> 9:1829-1838 (1994)
198	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer" <u>Nature</u> 396(6712):699-703 (1998)
199	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
200	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> " <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)
201	Plowman et al., "Ligand-specific activation of HER4/p180 <sup>erbB4</sup> , a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)
202	Pluckthun and Pack, "New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments" <u>Immunotechnology</u> (XP-004088466) 3:83-105 (June 1997)
203	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)
204	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
205	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <u>Blood</u> 83(2):435-445 (Jan 15, 1994)
206	Renshaw et al., "Humoral Immune Responses in CD40 Ligand-deficient Mice" <u>Journal of Experimental Medicine</u> 180:1889-1900 (1994)
207	Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-329 (Mar 24, 1988)
208	Sarup et al., "Characterization of an Anti-P185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)

Examiner

Misra 2

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

8,813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

209	Schaefer et al., "γ-Heregulin: A Novel Heregulin Isoform That is an Autocrine Growth Factor for the Human Breast Cancer Cell Line, MDA-MB-175" <u>Oncogene</u> 15:1385-1394 (1997)
210	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
211	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
212	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" <u>Journal of Experimental Medicine</u> 189:1747-1756 (1999)
213	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)
214	Schroff, R. et al., "Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy" <u>Cancer Research</u> 45:879-885 (1985)
215	Scott et al., "p185 <sup>HER2</sup> Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)
216	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)
217	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
218	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)
219	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)
220	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
221	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" <u>Journal of Immunology</u> 148(9):2918-2922 (1992)
222	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens" <u>J. Leukocyte Biol.</u> 65:680-683 (1999)
223	Shuford et al., "Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy" <u>Science</u> 252(5006):724-727 (May 3, 1991)
224	Sias et al., "ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids" <u>Journal of Immunological Methods</u> 132(1):73-80 (Aug 28, 1990)
225	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
226	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)
227	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)
228	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)

Examiner

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

DEC 18 2001

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |    |     |  |
|----|-----|--|
| my | 229 | Smith and Morrison, "Recombinant polymeric IgG: an approach to engineering more potent antibodies" <u>Bio/Technology</u> 12(7):683-688 (Jul 1994)  |
|    | 230 | Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)  |
|    | 231 | Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)   |
|    | 232 | Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)  |
|    | 233 | Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)   |
|    | 234 | Stevenson et al., "A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge" <u>Anti-Cancer Drug Design</u> 3(4):219-230 (1989)  |
|    | 235 | Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells With HER2/NEU Gene Amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991) |
|    | 236 | Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation" <u>The Journal of Immunology</u> 135(2):973-979 (1985)   |
|    | 237 | Tedder et al., "The CD20 surface molecule of B lymphocytes functions as a calcium channel" <u>J. Cell. Biochem.</u> (Abstract # M 023) 14D:195 (1990)  |
|    | 238 | Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)  |
|    | 239 | Tutt et al., "Trispecific F(ab') <sub>3</sub> Derivatives that Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" <u>J. Immunol.</u> 147(1):60-69 (1991)                                    |
|    | 240 | Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)   |
|    | 241 | Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)   |
|    | 242 | Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)   |
|    | 243 | Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes" <u>Journal of Biological Chemistry</u> 264(19):11282-11287 (Jul 5, 1989)   |
|    | 244 | Vassilev et al., "Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)" <u>Clin. Exp. Immunol.</u> 92:369-372 (Feb 25, 1993)   |
|    | 245 | Verhoeyen, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)  |
|    | 246 | Verma et al., "Rel/NF- $\kappa$ B/I $\kappa$ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)  |
|    | 247 | Vitetta and Uhr, "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)  |
| ✓  | 248 | von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)  |

Examiner

Misook

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce  
Patent and Trademark Office

P1780R1

09/813,341

(Use several sheets if necessary)

Applicant  
Miller et al.

Filing Date  
20 Mar 2001

Group  
1644

**OTHER DISCLOSURES** (Including Author, Title, Date, Pertinent Pages, et al.)


[illegible]

Examiner

Date Considered

3-10-05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
my	260	WO 02/08293	31.01.02	PCT				

RECEIVED  
MAR 05 2002  
TECH CENTER 1600/2900

Examiner


*mirosh y*

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
my	261	WO 92/22583	23.12.92	PCT				
<b>RECEIVED</b> APR 15 2002 TECH CENTER 1600/2900								

Examiner

Misovich

Date Considered

3-10-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1644

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
my	262	6,368,596	09.04.02	Ghetie et al.		TECH CENTER 1600/2900	

RECEIVED

MAY 06 2002

Examiner

Missed yr

Date Considered

3-8-03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1780R1		Serial No. 09/813,341	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Miller et al.			
				Filing Date 20 Mar 2001		Group 1642	
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>my</i>	263	6,515,110	04.02.03	Whitlow et al.			
Examiner <i>misook</i>				Date Considered 3-10-03			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1780R1

Serial No.

09/813,341

Applicant

Miller et al.

Filing Date

20 Mar 2001

Group

1642

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
my	264	6,476,198	05.11.02	Kang, A.			

**RECEIVED**  
MAR 28 2003  
TECH CENTER 1600/2900

Examiner

misch

Date Considered

1-28-04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.